RECRUITING

A Phase 1/2 Study of NRTX-1001 Neuronal Cell Therapy in Drug-Resistant Bilateral Mesial Temporal Lobe Epilepsy (MTLE)

Talk to us

Conditions

Epilepsy, Temporal LobeBilateral Temporal Lobe EpilepsyBilateral MTLERefractory Bilateral MTLE

Quick Navigation

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

This is a multicenter, single arm, open label clinical trial that is designed to test the safety and preliminary efficacy of single administration inhibitory nerve cells called interneurons (NRTX-1001), into both temporal lobes of subjects with drug-resistant bilateral mesial temporal lobe epilepsy.

Official Title

A Phase 1/2 Study of NRTX-1001 Neuronal Cell Therapy in Drug-Resistant Bilateral Temporal Lobe Epilepsy (MTLE)

Quick Facts

Study Start:2024-11-14
Study Completion:2040-07-15
Study Type:Not specified
Phase:Not Applicable
Enrollment:Not specified
Status:RECRUITING

Study ID

NCT06422923

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:18 Years to 75 Years
Sexes Eligible for Study:ALL
Accepts Healthy Volunteers:No
Standard Ages:ADULT, OLDER_ADULT
Inclusion CriteriaExclusion Criteria
  1. 1. Male or female, age 18-75 years.
  2. 2. Subjects of childbearing potential will use highly effective contraception.
  3. 3. Proven history of focal seizures of hippocampal origin with bilateral seizure foci confirmed by scalp or intracranial ictal EEG (including confirmation by recordings from responsive neurostimulation \[RNS\] electrodes when applicable).
  4. 4. Either
  5. 1. bilateral hippocampal sclerosis on MRI (evidenced by increased FLAIR signal intensity in both hippocampi or by visual assessment showing reduced volume compared to normal) or
  6. 2. bilateral temporal hypometabolism on 18-Flourodeoxyglucose Positron Emission Tomography (FDG PET) (assessed by visual assessment, comparing temporal regions to frontal/parietal lobe neocortex). In this case, ictal EEG recordings must also include intracranial confirmation.
  7. 3. a combination of unilateral instances of the evidence described in a. and b. (e.g., one side can be evidenced by criterion a. and the other side by criterion b.) MRI or PET scans used for assessment must have been acquired within 3 years of screening.
  8. 5. Subject has had at least four clinical focal seizures, including at least two clinical focal seizures with objective manifestations, on average, per month for the 6 months prior to screening.
  9. 6. Subject has previously had adequate (in opinion of investigator) therapeutic trials of at least two Anti-Seizure Medicines (ASMs).
  10. 7. Current ASM regimen, and doses of other drugs known to affect seizure frequency (e.g., antidepressants), have been stable for at least three months prior to enrollment.
  11. 8. Subject can converse and read in English or Spanish. Able to participate in required study procedures and provide signed informed consent.
  1. 1. Epilepsy due to other and/or progressive neurologic disease.
  2. 2. Evidence of seizure focus outside hippocampus (either by seizure semiology or EEG findings).
  3. 3. MRI indicating potential malignant lesion (low-grade glioma of any type is excluded) in any location or non-malignant potentially epileptogenic lesion outside the hippocampus. Small (\<2 cm) non invasive meningioma, remote from the affected temporal lobe, is not exclusionary.
  4. 4. Seizures of non-focal origin.
  5. 5. History of status epilepticus in the year prior to screening, as guided by ILAE criteria (Trinka 2015) in the judgement of the PI. A history of cluster seizures is permitted.
  6. 6. Psychogenic Non-Epileptic Seizures (PNES) within the past 3 years.
  7. 7. Severe psychiatric disorders.
  8. 8. Primary or secondary immunodeficiency.
  9. 9. Pregnancy, or currently breastfeeding.
  10. 10. Suicide attempts in past year.
  11. 11. Significant other medical conditions which would impair safe participation.

Contacts and Locations

Study Contact

Holly Finefrock, BSHS
CONTACT
650-436-3045
holly@neuronatx.com
Sheri Madrid, BS, BA
CONTACT
949-500-0027
sheri@neuronatx.com

Principal Investigator

John Hixson, MD
STUDY_DIRECTOR
Neurona Therapeutics

Study Locations (Sites)

Stanford University
Palo Alto, California, 94304
United States
University of California San Diego
San Diego, California, 92037
United States
University of California San Francisco
San Francisco, California, 94143
United States
University of Chicago
Chicago, Illinois, 60637
United States

Collaborators and Investigators

Sponsor: Neurona Therapeutics

  • John Hixson, MD, STUDY_DIRECTOR, Neurona Therapeutics

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2024-11-14
Study Completion Date2040-07-15

Study Record Updates

Study Start Date2024-11-14
Study Completion Date2040-07-15

Terms related to this study

Keywords Provided by Researchers

  • Bilateral Temporal Lobe Epilepsy
  • Bilateral MTLE
  • Refractory Bilateral MTLE

Additional Relevant MeSH Terms

  • Epilepsy, Temporal Lobe